睿知中国医院研究地图
候选清单

正在招募胶质瘤不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Recurrent High Grade Glioma Treated by LITT

ClinicalTrials.gov 上登记的一项胶质瘤开放试验,由首都医科大学附属北京天坛医院牵头,本站收录的另外 7 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patients with previous pathological diagnosis of 2021 World Health Organization Classification of Central Nervous System Tumors (WHO CNS5) grade 3 or 4 glioma and received standard treatment;

    入选标准第 2 条

    Pathology shows progression or recurrence;

    入选标准第 6 条

  3. At least one image other than T1 contrast indicates progression;

    入选标准第 5 条

    All tumor lesions are located supratentorial and the maximum cross-sectional short-axis length in the T1 contrast is ≤30 mm;

    入选标准第 8 条

  4. Karnofsky score (KPS) ≥ 60 and the patient can tolerate the intervention;

    入选标准第 9 条

  5. Women who are pregnant, lactating, or planning to become pregnant within 6 months;

    排除标准第 5 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06161610,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Aged 18 years old or above;
  2. Patients with previous pathological diagnosis of 2021 World Health Organization Classification of Central Nervous System Tumors (WHO CNS5) grade 3 or 4 glioma and received standard treatment;
  3. Meet any of the following:
  4. Meets the disease progression criteria in the Response Evaluation of Neuro-Oncology (RANO 2.0) criteria;
  5. At least one image other than T1 contrast indicates progression;
  6. Pathology shows progression or recurrence;
  7. Other progress determined by the Clinical Events Committee (CEC);
  8. All tumor lesions are located supratentorial and the maximum cross-sectional short-axis length in the T1 contrast is ≤30 mm;
  9. Karnofsky score (KPS) ≥ 60 and the patient can tolerate the intervention;
  10. The subjects or their agent can understand the purpose of the trial, show sufficient compliance with the trial protocol, and sign the informed consent form.

排除标准:Exclusion Criteria:

  1. Patients may benefit from other treatments or may not benefit from this trial;
  2. No more than three months since the patient underwent craniotomy;
  3. MRI contrast cannot be performed;
  4. Severe coagulation disorder;
  5. Women who are pregnant, lactating, or planning to become pregnant within 6 months;
  6. Participated in any other clinical trials of drugs or medical devices within 3 months;
  7. Combined diseases that may interfere with treatment or prognosis assessment;
  8. Refuse or unlikely to complete follow-up assessment;
  9. Other circumstances in which the researcher deems it inappropriate to participate in this clinical trial.

引自 ClinicalTrials.gov, NCT06161610, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06161610,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06161610